Related Topics:
Facility ID: 01432PHRMC25PAT
Facility Name and Address: VERANOVA L.P. 25 PATTON RD DEVENS, MA 01434 Parent Company: VERANOVA BIDCO L.P. Industry: Pharmaceutical Preparation Manufacturing (325412) Chemical: Methanol Reports: View TRI Facility profile report for this facility View TRI Form R submissions by this facility |
|
*You can navigate within the map with your mouse. |
Production Related Waste Management for Selected Chemical
lchemid=0000067561
Chart Options1: |
Waste Management Comparison -
Display facility comparison report for this industry and chemical
Display facility comparison report for this parent company
Pollution Prevention Activities for Selected Chemical
Reporting Year | Section 8.10: Newly Implemented Source Reduction Activity | Section 8.10: Methods to Identify Activity | Section 8.11: Optional Pollution Prevention Information* |
---|---|---|---|
2019 |
Source Reduction:: W71: Other cleaning and degreasing modifications
|
Methods to Identify SR Opportunities: T05: Employee recommendation (independent of a formal company program)
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction. |
W71: When possible, methanol will be reused for cleaning processes within campaigns. This may be permitted by the client and when acceptable this can reduce the use of methanol by 1 drum per client's batch. Source Reduction - Reusing solvents for repeat cleanings was offered by production coordinators and project managers must receive approval from client representatives before proceeding. Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - JM IS A CONTRACT PHARMACEUTICAL MANUFACTURING AND RESEARCH FIRM WHICH MANUFACTURES PRODUCTS ON A BATCH BASIS BY CLIENT. THE CLIENTS PROJECTS DICTATE THE CHEMICALS USED AND THE QUANTITIES. AS THESE PRODUCTS MAY BE IN FDA APPROVAL PROCESS OR ALREADY FDA APPROVED JM HAS LITTLE OPPORTUNITY TO ENCOURAGE LESS HAZARDOUS CHEMICAL SUBSTITUTIONS. WHEN POSSIBLE IN EARLY STAGES OF WORKING WITH NEW CLIENT, JM WILL OFFER TO OPTIMIZE PROCESS WHICHMAY RESULT IN LESS CHEMICALS USED OVERALL BY REDUCING NUMBER OF FILTRATIONS, WASHES, ETC. |
2018 |
Source Reduction:: W71: Other cleaning and degreasing modifications[-0-4%]
|
Methods to Identify SR Opportunities: T05: Employee recommendation (independent of a formal company program)
|
W71: When possible, methanol will be reused for cleaning processes within campaigns. This may be permitted by the client and when acceptable this can reduce the use of methanol by 1 drum per client's batch. Source Reduction - Reusing solvents for repeat cleanings was offered by production coordinators and project managers must receive approval fromclient representatives before proceeding. |
2017 |
Other Barriers to Source Reduction - JM IS A CONTRACT PHARMACEUTICAL MANUFACTURING AND RESEARCH FIRM WHICH MANUFACTURES PRODUCTS ON A BATCH BASIS BY CLIENT. THE CLIENTS PROJECTS DICTATE THE CHEMICALS USED AND THE QUANTITIES. AS THESE PRODUCTS MAY BE IN FDA APPROVAL PROCESS OR ALREADY FDA APPROVED JM HAS LITTLE OPPORTUNITY TO ENCOURAGE LESS HAZARDOUS CHEMICAL SUBSTITUTIONS. WHEN POSSIBLE IN EARLY STAGES OF WORKING WITH NEW CLIENT, JM WILL OFFER TO OPTIMIZE PROCESS WHICH MAY RESULT IN LESS CHEMICALS USED OVERALL BY REDUCING NUMBER OF FILTRATIONS, WASHES, ETC. Other Environmental Practices: Energy Recovery - JM waste disposal vendors seek energy recovery disposal options whenever possible. |
||
2016 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
|
Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - JM is a pharmaceutical contract manufacturing organization that manufactures Active Pharmaceutical Ingredients and intermediates based on clients' project requirements. Depending on whether an API or intermediate is in an FDA approval phase, chemical substitutions will not be permitted by the client. This factors heavily into whether a source reduction activities may be undertaken. Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - Active pharmaceutical ingredients and intermediates are made using the development methods and materials required by the clients. If an API is going through clinical trials or development, clients will not allow chemical substitutions due to concerns regarding any FDA submittals that have been processed or are being processed. Chemical changes may affect the FDA submittal and can result in FDA rejection of a phase 1, 2 or 3 submittal. |
|
2015 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
|
Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - Active pharmaceutical ingredients and intermediates are made using the development methods and materials required by the clients. If an API is going through clinical trials or development, clients will not allow chemical substitutions due to concerns regarding any FDA submittals that have been processed or are being processed. |
|
2014 |
Other Barriers to Source Reduction - The batch process schedule and the clients JMPS is contracted with determine the chemicals used and the chemical amounts required. If a client's product is in the process of FDA approval or has been FDA approved, chemical substitutions cannot be made. |
||
2013 |
Source Reduction:: W58: Other process modifications
|
Methods to Identify SR Opportunities: T11: Other
|
W58: The operations team reviews the processes to determine if there opportunities to reduce or reuse solvents. This is process dependent and must be approved by the clients. Source Reduction - When possible the distillates from the project may be reused to further process materials. If this can be done it reduces the amount of virgin solvent needed. Distillates may also be used for within campaign cleaning and this negates the need for new solvent. These steps are possible if the process allows for them and if the client is agreeable to them. |
2012 |
Other Barriers to Source Reduction - The particular chemistry performed by the site in the production of client specific compounds requires use of certain solvents. Efforts are made to substitute less hazardous chemicals when possible but this is not feasible in most circumstances. |